Sector News

Former Teva generics chief Olafsson steps into CEO seat at growth-challenged Hikma

February 20, 2018
Life sciences

Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as new CEO of Jordan’s Hikma Pharmaceuticals.

The company trumpeted the appointment Tuesday, noting that current CEO Said Darwazah would slide over into the executive chairman’s spot. In a statement, Darwazah praised Olafsson’s “deep sector knowledge” and “proven ability to drive growth,” adding that “we are delighted that Siggi is joining Hikma as our new CEO.”

In a major—and unwelcome—surprise to Teva shareholders, Olafsson left his long-held post at the Israeli company in December 2016.

The news stirred up big concerns about the drugmaker’s then-recent $40.5 billion purchase of Allergan’s generics unit. After all, Olafsson had been “a champion” of that deal, Credit Suisse analyst Vamil Divan said at the time.

Turns out that concern was warranted. Pricing pressure mounted on the generics sector, and Teva got hit hard.

Olafsson’s was just the first in a string of executive departures that continued throughout 2017, culminating in a revamped executive structure engineered by new CEO Kåre Schultz. And that revamp eliminated Dipankar Bhattacharjee, Olafsson’s replacement.

Meanwhile, Hikma’s investors celebrated the CEO switch Tuesday, though Jefferies analyst James Vane-Tempest cautioned in a note to clients that “any improvements are likely to be gradual.”

“2018 in our view is still likely to be tough,” he wrote, adding that Hikma “is still challenged by near-term headwinds, and we believe that full-year results on March 14 could disappoint for a number of reasons.”

A couple of those reasons? More competition in generic injectables and the “potential for larger write-downs” at recent buy Roxane Labs.

Investors are also still waiting for word on Hikma’s copy of GlaxoSmithKline respiratory heavyweight Advair after the November news that Hikma and partner Vectura were locked in a dispute with the FDA. An update is expected later this quarter.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 21, 2021

Johnson & Johnson to focus on pharmaceuticals

Life sciences

Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.

November 21, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform

Life sciences

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.

November 21, 2021

What are the benefits of the digital health revolution?

Life sciences

Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless

Send this to a friend